Page 1095 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 60 Myelodysplastic Syndromes 969.e9

366. Broseus J, Alpermann T, Wulfert M, et al: Age, JAK2(V617F) and 388. Schouten HC, Vellenga E, van Rhenen DJ, et al: Recombinant human
SF3B1 mutations are the main predicting factors for survival in erythropoietin in patients with myelodysplastic syndromes. Leukemia
refractory anaemia with ring sideroblasts and marked thrombocytosis. 5(5):432–436, 1991.
Leukemia 27(9):1826–1831, 2013. 389. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al: A validated
367. Ceesay MM, Lea NC, Ingram W, et al: The JAK2 V617F mutation is decision model for treating the anaemia of myelodysplastic syndromes
rare in RARS but common in RARS-T. Leukemia 20(11):2060–2061, with erythropoietin + granulocyte colony-stimulating factor: significant
2006. effects on quality of life. Br J Haematol 120(6):1037–1046, 2003.
368. Remacha A, Puget G, Nomdedéu JF, et al: Occurrence of the JAK2 390. Park S, Grabar S, Kelaidi C, et al: Predictive factors of response and
V617F mutation in the WHO provisional entity: Myelodysplastic/ survival in myelodysplastic syndrome treated with erythropoietin and
myeloproliferative disease, unclassifiable-refractory anemia with ringed G-CSF: the GFM experience. Blood 111(2):574–582, 2008.
sideroblasts associated with marked thrombocytosis. Haematologica 391. Rigolin GM, Porta MD, Ciccone M, et al: In patients with myelodys-
91:719–720, 2006. plastic syndromes response to rHuEPO and G-CSF treatment is related
369. Cheson BD, Bennett JM, Kantarjian H, et al: Report of an international to an increase of cytogenetically normal CD34 cells. Br J Haematol
working group to standardize response criteria for myelodysplastic 126(4):501–507, 2004.
syndromes. Blood 96(12):3671–3674, 2000. 392. Musto P, Matera R, Minervini MM, et al: Low serum levels of tumor
370. Jansen AJG, Essink-Bot M-L, Beckers EAM, et al: Quality of life necrosis factor and interleukin-1 beta in myelodysplastic syndromes
measurement in patients with transfusion-dependent myelodysplastic responsive to recombinant erythropoietin. Haematologica 79(3):265–
syndromes. Br J Haematol 121(2):270–274, 2003. 268, 1994.
371. Abel GA, Klaassen R, Lee SJ, et al: Patient-reported outcomes for the 393. Goy A, Belanger C, Casadevall N, et al: High doses of intravenous
myelodysplastic syndromes: a new MDS-specific measure of quality of recombinant erythropoietin for the treatment of anaemia in myelodys-
life. Blood 123(3):451–452, 2014. plastic syndrome. Br J Haematol 84(2):232–237, 1993.
372. Hellstrom-Lindberg E, Malcovati L: Supportive care and use of hema- 394. Stasi R, Abruzzese E, Lanzetta G, et al: Darbepoetin alfa for the treat-
topoietic growth factors in myelodysplastic syndromes. Semin Hematol ment of anemic patients with low- and intermediate-1-risk myelodys-
45(1):14–22, 2008. plastic syndromes. Ann Oncol 16(12):1921–1927, 2005.
373. Cazzola M, Malcovati L: Myelodysplastic syndromes–coping with 395. Moyo V, Lefebvre P, Duh MS, et al: Erythropoiesis-stimulating agents
ineffective hematopoiesis. N Engl J Med 352(6):536–538, 2005. in the treatment of anemia in myelodysplastic syndromes: a meta-
374. Hebert P, Wells G, Blajchman M, et al: A multicenter, randomized, con- analysis. Ann Hematol 87(7):527–536, 2008.
trolled clinical trial of transfusion requirements in critical care. Transfus 396. Terpos E, Mougiou A, Kouraklis A, et al: Prolonged administration of
Requir Crit Care Care Trials Group. N Engl J Med 340(6):409–417, erythropoietin increases erythroid response rate in myelodysplastic syn-
1999. dromes: a phase II trial in 281 patients. Br J Haematol 118(1):174–180,
375. Hajjar LA, Vincent J-L, Galas FRBG, et al: Transfusion requirements 2002.
after cardiac surgery: the TRACS randomized controlled trial. JAMA 397. Verhoef GE, Zachée P, Ferrant A, et al: Recombinant human erythro-
304(14):1559–1567, 2010. poietin for the treatment of anemia in the myelodysplastic syndromes:
376. Fakhry S, Fata P: How low is too low? Cardiac risks with anemia. Crit a clinical and erythrokinetic assessment. Ann Hematol 64(1):16–21,
Care 8(Suppl 2):S11–S14, 2004. 1992.
377. Oliva EN, Schey C, Hutchings AS: A review of anemia as a cardiovas- 398. Kurzrock R, Talpaz M, Estey E, et al: Erythropoietin treatment in
cular risk factor in patients with myelodysplastic syndromes. Am J Blood patients with myelodysplastic syndrome and anemia. Leukemia
Res 1(2):160–166, 2011. 5(11):985–990, 1991.
378. Anderson KC, Weinstein HJ: Transfusion-associated graft-versus-host 399. Spiriti MAA, Latagliata R, Niscola P, et al: Impact of a new dosing
disease. N Engl J Med 323(5):315–321, 1990. regimen of epoetin alfa on quality of life and anemia in patients with
379. Chacko J, Pennell DJ, Tanner MA, et al: Myocardial iron loading by low-risk myelodysplastic syndrome. Ann Hematol 84(3):167–176,
magnetic resonance imaging T2* in good prognostic myelodysplastic 2005.
syndrome patients on long-term blood transfusions. Br J Haematol 400. Jadersten M, Malcovati L, Dybedal I, et al: Erythropoietin and
138(5):587–593, 2007. granulocyte-colony stimulating factor treatment associated with
380. Pascal L, Beyne-Rauzy O, Brechignac S, et al: Cardiac iron overload improved survival in myelodysplastic syndrome. J Clin Oncol
assessed by T2* magnetic resonance imaging and cardiac function in 26(21):3607–3613, 2008.
regularly transfused myelodysplastic syndrome patients. Br J Haematol 401. Hellström-Lindberg E, Negrin R, Stein R, et al: Erythroid response to
162(3):413–415, 2013. treatment with G-CSF plus erythropoietin for the anaemia of patients
381. Malcovati L: Impact of transfusion dependency and secondary iron with myelodysplastic syndromes: proposal for a predictive model. Br J
overload on the survival of patients with myelodysplastic syndromes. Haematol 99(2):344–351, 1997.
Leuk Res 31(Suppl 3):S2–S6, 2007. 402. Rizzo JD, Brouwers M, Hurley P, et al: American Society of Hematology/
382. Chee CE, Steensma DP, Wu W, et al: Neither serum ferritin nor the American Society of Clinical Oncology clinical practice guideline
number of red blood cell transfusions affect overall survival in refrac- update on the use of epoetin and darbepoetin in adult patients with
tory anemia with ringed sideroblasts. Am J Hematol 83(8):611–613, cancer. Blood 116(20):4045–4059, 2010.
2008. 403. Phrommintikul A, Haas SJ, Elsik M, et al: Mortality and target haemo-
383. Rose EH, Abels RI, Nelson RA, et al: The use of r-HuEpo in the globin concentrations in anaemic patients with chronic kidney disease
treatment of anaemia related to myelodysplasia (MDS). Br J Haematol treated with erythropoietin: a meta-analysis. Lancet 369(9559):381–388,
89(4):831–837, 1995. 2007.
384. Bessho M, Jinnai I, Matsuda A, et al: Improvement of anemia by 404. NCCN practice guidelines for the myelodysplastic syndromes. Natl
recombinant erythropoietin in patients with myelodysplastic syndromes Compr Cancer Netw Oncol Williston Park 12:53, 1998.
and aplastic anemia. Int J Cell Cloning 8(6):445–458, 1990. 405. Vadhan-Raj S, Keating M, LeMaistre A, et al: Effects of recombinant
385. Stebler C, Tichelli A, Dazzi H, et al: High-dose recombinant human human granulocyte-macrophage colony-stimulating factor in patients
erythropoietin for treatment of anemia in myelodysplastic syndromes with myelodysplastic syndromes. N Engl J Med 317(25):1545–1552,
and paroxysmal nocturnal hemoglobinuria: a pilot study. Exp Hematol 1987.
18(11):1204–1208, 1990. 406. Antin JH, Smith BR, Holmes W, et al: Phase I/II study of recom-
386. Bowen D, Culligan D, Jacobs A: The treatment of anaemia in the binant human granulocyte-macrophage colony-stimulating factor in
myelodysplastic syndromes with recombinant human erythropoietin. aplastic anemia and myelodysplastic syndrome. Blood 72(2):705–713,
Br J Haematol 77(3):419–423, 1991. 1988.
387. Hellstrom E, Birgegard G, Lockner D, et al: Treatment of myelo- 407. Negrin RS, Haeuber DH, Nagler A, et al: Treatment of myelodysplastic
dysplastic syndromes with recombinant human erythropoietin. Eur J syndromes with recombinant human granulocyte colony-stimulating
Haematol 47(5):355–360, 1991. factor. A phase I-II trial. Ann Intern Med 110(12):976–984, 1989.